Editorial: Inflammatory factors in coronary heart disease: mechanism, diagnosis, and therapy

articles are meta-analysis or review.Wei et al. found that edgeworthia gardneri (Wall.) Meisn. extract protects against myocardial infarction by inhibiting NF-κB-and MAPK-mediated endothelial inflammation, indicating EG as a potential therapeutic agent in ischemic cardiovascular disease [Front. Cardiovasc. Med. 9:1013013.doi: 10.3389/fcvm.2022.1013013]. Furthermore, zuo et al. established remote ischemic postconditioning (RIPostC) model at rat, and revealed that RIPostC could markedly decrease infarct size and reduce the levels of cardiac IL-1β, IL-6 and increase the level of cardiac IL-10, which was negatively correlated with ADAMTS15 by transcriptome analysis [Front. Cardiovasc. Med. 10:1089151.doi: 10.3389/fcvm.2023.1089151]. Next, the role and the mechanism of inflammation-related gene ADAMTS15 should be investigated. Another, wang et al. identified 5 potential biomarkers (SERPINA3, FCN3, PTN, CD163, and SCUBE2) in human ischemic cardiomyopathy (ICM) via datasets, and performed the functional experiment in the ICM rat, which could potentially provide clinicians with a helpful tool to the diagnosis and treatment of ICM from an inflammatory perspective [Front. Cardiovasc. Med. 9:972274. doi: 10.3389/fcvm.2022.972274].In another study [Front. Cardiovasc. Med. 9:1008212. doi: 10.3389/fcvm.2022.1008212], mean platelet volume lymphocyte ratio (MPVLR) was calculated in patients with chronic total occlusion (CTO), and the relationships between MPVLR and coronary collateral circulation (CCC) formation were analyzed. The results revealed that MPVLR was negatively correlated with CCC and a high MPVLR level was an independent predictor of poorly formed CCC, which means a simple and practical method. Xiong et al. revealed the sLAG3 level was significantly lower in the coronary artery disease (CAD) vs. the controls, and the sLAG3 level was negatively associated with the occurrence but not severity of CAD. Meanwhile, the sLAG3 was negatively associated with BMI and diabetes mellitus, suggesting the reduced sLAG3 might be a novel risk factor for developing CAD [Front. Cardiovasc. Med. 9:988582. doi: 10.3389/fcvm.2022.988582 In addition, frontiers and hotspots evolution in anti-inflammatory studies for coronary heart disease over the past 30 years are summarized, and a total of 5,818 articles focus on anti-inflammatory studies in CHD [Front. Cardiovasc. Med. 10:1038738.doi: 10.3389/fcvm.2023.1038738], which is of great significance for future studies. Another meta-analysis by Liu et al includes a total of 23 studies about CRP and MACE, and suggests that CRP is a prospective predictor of the prognosis in patients with AMI undergoing PCI, especially in hospitalization and short-term and in the Asian group [Front. Cardiovasc. Med. 9:1013501. doi: 10.3389/fcvm.2022.1013501]. In China, Danhong injection (DHI) is recommended by expert consensus and is widely used in the perioperative management of patients with acute coronary syndrome (ACS), a systematic review and meta-analysis by Li et al. demonstrates that the combination of DHI and conventional therapy results in a better therapeutic effect than that observed with conventional therapy alone in patients with ACS by inhibiting inflammation [Front. Cardiovasc. Med. 9:1029387.doi: 10.3389/fcvm.2022.1029387]. Kawasaki disease (KD) is an acute, inflammation mediated vasculitis, mainly affecting in children under five, which is consider as the most common coronary artery disease in children. A series of studies have determined vascular endothelial cells damages and dysfunction in KD patients. In the review by Qiu et al, the role of endothelial cells in the pathogenesis of KD and the therapeutic methods for endothelial cells were systematically described [Front. Cardiovasc. Med. 9:981010. doi: 10.3389/fcvm.2022.981010].In summary, above 11 article in this topic cover multiple themes as follows: the cellular and molecular mechanisms of inflammatory factors in CHD, the effects of inflammatory factors on CHD, inflammatory factors as biomarkers of CHD, as well as a review about the clinical outcomes of CHD therapeutics by targeting inflammatory factors.